Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDNF Extension Study in Parkinson's Disease
NCT03775538Phase 2Completed
- Sponsor
- Herantis Pharma
- Start
- Jul 2018
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of cerebral dopamine neurotrophic factor in Parkinson's disease (PD) (2 arms), sponsored by Herantis Pharma. Primary endpoints: Incidence of treatment-emergent adverse events, Change in Electrocardiogram at Week 65 and 7 more. Started Jul 2018; status: completed.
02
Drugs
cerebral dopamine neurotrophic factor
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03775538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775538.